Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harrison Linder

Interventional Pain Medicine Baltimore, MD Medical Doctor

NPI 1245596139 CMS profile 4222978

345 Saint Paul St Fl 4, Baltimore, MD 21202

Open in the dashboard

General payments

$1,440

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harrison Linder of Baltimore, MD is reported in the CMS Open Payments database as having received $1,440 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $171 3
2024 General $64 3
2023 General $238 10
2022 General $435 10
2021 General $159 7
2020 General $233 5
2019 General $140 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harrison Linder
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Harrison Linder were reported at $171. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Harrison Linder Interventional Pain Medicine median Middle half National median
2019 $140 $684 $216–$2,079 $163
2020 $233 $382 $122–$1,109 $114
2021 $159 $552 $167–$1,554 $132
2022 $435 $605 $187–$1,924 $149
2023 $238 $671 $195–$1,915 $160
2024 $64 $684 $206–$1,837 $164
2025 $171 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $431 10 payments
  2. Boston Scientific Corporation $234 9 payments
  3. Abbott Laboratories $167 7 payments
  4. Stimwave Technologies Incorporated $153 2 payments
  5. Globus Medical, Inc. $149 2 payments
  6. Pfizer Inc. $46 3 payments
  7. Averitas Pharma Inc. $45 2 payments
  8. IBSA Pharma Inc. $35 2 payments
  9. SI-BONE, Inc. $29 1 payment
  10. Acacia Pharma Inc $24 1 payment
  11. Other $129 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,440 46 payments
Products named General payments · program years 2019–2025
  1. Omnia $360 7 payments
  2. WaveWriter Alpha Prime 16 $161 5 payments
  3. Senza $149 2 payments
  4. CFNS StimQ Peripheral Nerve StimulatorSystem $138 1 payment
  5. SCS FreedonSpinal Cord Stimulator $138 1 payment
  6. PROCLAIM $96 4 payments
  7. Senza Spinal Cord Stimulation System $55 2 payments
  8. Qutenza $45 2 payments
  9. Licart $35 2 payments
  10. IFUSE IMPLANT $29 1 payment
  11. Other $467 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,361

Median for Pain Management: 951

Drug cost

$16,410

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 526 $5,476
Baclofen Generic 447 $5,345
Pregabalin Generic 99 $2,449
Methocarbamol Generic 42 $873
Tizanidine Hcl Generic 56 $544
Duloxetine Hcl Generic 13 $507
Cyclobenzaprine Hcl Generic 52 $438
Methylprednisolone Generic 41 $313
Meloxicam Generic 57 $249
Diclofenac Sodium Generic 15 $122

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$145,118

Medicare's payments for the services billed

Medicare patients

658

Average age 73

Services billed

1,944

430 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Ischemic heart disease 29%
Depression 27%
Chronic kidney disease 20%
COPD 18%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record